Phase II study of depsipeptide [FR901228, romidepsin] in metastatic neuroendocrine tumors

Trial Profile

Phase II study of depsipeptide [FR901228, romidepsin] in metastatic neuroendocrine tumors

Discontinued
Phase of Trial: Phase II

Latest Information Update: 03 Jun 2013

At a glance

  • Drugs Romidepsin (Primary)
  • Indications Neuroendocrine carcinoma
  • Focus Pharmacogenomic; Therapeutic Use
  • Most Recent Events

    • 03 Jun 2013 Status changed from active, no longer recruiting to discontinued as reported by ClinicalTrials.gov.
    • 14 Dec 2012 Planned number of patients changed from 16 to 25 as reported by ClinicalTrials.gov record.
    • 18 Sep 2005 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top